-
摘要: 高白细胞急性白血病为血液科危重症，早期死亡风险高，其具有独特的临床表现、流行病学特征及病理生理学机制。白细胞淤滞、肿瘤溶解综合征和弥散性血管内凝血是其常见的近期并发症，对于此类患者，应根据不同情况选择合适的治疗方案并进行密切监测以减少早期死亡风险，为后续治疗提供时机。Abstract: Hyperleukocytic acute leukemia is a critical disease in the department of hematology with a high risk of early death. It has unique clinical manifestations, epidemiological characteristics and pathophysiological mechanisms. Leukostasis, tumor lysis syndrome and disseminated intravascular coagulation are common short-term complications. For such patients, appropriate treatment should be selected according to different conditions and close monitoring should be performed to reduce the risk of early death and provide time for subsequent treatment.
-
-
[1] Ali AM, Mirrakhimov AE, Abboud CN, et al. Leukostasis in adult acute hyperleukocytic leukemia: a clinician's digest[J]. Hematol Oncol, 2016, 34(2): 69-78. doi: 10.1002/hon.2292
[2] Fodil S, Chevret S, Rouzaud C, et al. Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications[J]. PLoS One, 2022, 17(7): e0270744. doi: 10.1371/journal.pone.0270744
[3] Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia[J]. Blood, 125(21): 3246-3252. doi: 10.1182/blood-2014-10-551507
[4] Bewersdorf JP, Zeidan AM. Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?[J]. Cells, 2020, 9(10): 2310. doi: 10.3390/cells9102310
[5] Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs. 60 mg/m2 in AML induction: Results from the UK NCRI AML17 trial in 1206 patients[J]. Blood, 2015, 125(25): 3878-3885. doi: 10.1182/blood-2015-01-623447
[6] Pastore F, Pastore A, Wittmann G, et al. The role of therapeutic leukapheresis in hyperleukocytotic AML[J]. PLoS One, 2014, 9(4): e95062. doi: 10.1371/journal.pone.0095062
[7] Feng S, Zhou L, Zhang X, et al. Impact Of ELN Risk Stratification, Induction Chemotherapy Regimens And Hematopoietic Stem Cell Transplantation On Outcomes In Hyperleukocytic Acute Myeloid Leukemia With Initial White Blood Cell Count More Than 100×109/L[J]. Cancer Manag Res, 2019, 11: 9495-9503. doi: 10.2147/CMAR.S225123
[8] Daver N, Kantarjian H, Marcucci G, et al. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis[J]. Br J Haematol, 2015, 168(5): 646-653. doi: 10.1111/bjh.13189
[9] Shallis RM, Stahl M, Bewersdorf JP, et al. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: A contemporary appraisal of outcomes and benefits[J]. Expert Rev Hematol, 2020, 13(5): 489-499. doi: 10.1080/17474086.2020.1751609
[10] Schoch C, Schnittger S, Klaus M, et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: Incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases[J]. Blood, 2003, 102(7): 2395-2402. doi: 10.1182/blood-2003-02-0434
[11] Largeaud L, Bertoli S, Bérard E, et al. Genomic landscape of hyperleukocytic acute myeloid leukemia[J]. Blood Cancer J, 2022, 12(1): 4. doi: 10.1038/s41408-021-00601-5
[12] Tien FM, Hou HA, Tsai CH, et al. Hyperleukocytosis is associated distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients[J]. Eur J Haematol, 2018, 101(1): 86-94. doi: 10.1111/ejh.13073
[13] Pastore F, Pastore A, Rothenberg-Thurley M, et al. Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis[J]. Cancer, 2022, 128(24): 4213-4222. doi: 10.1002/cncr.34495
[14] Thapa N, Pham R, Cole C, et al. Therapeutic leukocytapheresis in infants and children with leukemia and hyperleukocytosis: a single institution experience[J]. J Clin Apheresis, 2018, 33(3): 316-323. doi: 10.1002/jca.21610
[15] Liu Y, Issah MA, Hu X, et al. Fatal hyperleukocytic T lymphoblastic lymphoma/leukemia complicated with multi-gene fusion and mutation: clinical revelation and perception[J]. Am J Blood Res, 2020, 10(6): 440-446.
[16] Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update[J]. Blood Cancer J, 2017, 7(6): e577. doi: 10.1038/bcj.2017.53
[17] Macaron W, Sargsyan Z, Short NJ. Hyperleukocytosis and leukostasis in acute and chronic leukemias[J]. Leuk Lymphoma, 2022, 63(8): 1780-1791. doi: 10.1080/10428194.2022.2056178
[18] Coiffier B, Altman A, Pui CH, et al. Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review[J]. J Clin Oncol, 2008, 26(16): 2767-2778. doi: 10.1200/JCO.2007.15.0177
[19] Lad D, Jain A, Varma S. Complications and management of coagulation disorders in leukemia patients[J]. Blood Lymphat Cancer, 2017, 7: 61-72. doi: 10.2147/BLCTT.S125121
[20] Dicke C, Amirkhosravi A, Spath B, et al. Tissue factor-dependent and-independent pathways of systemic coagulation activation in acute myeloid leukemia: A single-center cohort study[J]. Exp Hematol Oncol, 2015, 4: 22. doi: 10.1186/s40164-015-0018-x
[21] Novotny JR, Müller-Beissenhirtz H, Herget-Rosenthal S, et al. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome[J]. Eur J Haematol, 2005, 74(6): 501-510. doi: 10.1111/j.1600-0609.2005.00421.x
[22] Grund FM, Armitage JO, Burns P. Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia[J]. Arch Intern Med, 1977, 137(9): 1246-1247. doi: 10.1001/archinte.1977.03630210112032
[23] Oberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and Meta-analysis[J]. Leuk Res, 2014, 38(4): 460-468. doi: 10.1016/j.leukres.2014.01.004
[24] Kim K, Konopleva M, DiNardo CD, et al. Urgent cytoreductive chemotherapy for newly diagnosed patients with AML is safe and feasible and facilitates enrollment on investigational clinical trials[J]. Blood, 2020, 136(Supplement 1): 2-4.
[25] Zhao J, Bewersdorf JP, Jaszczur S, et al. High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis[J]. Leuk Lymphoma, 2021, 62(5): 1195-1202. doi: 10.1080/10428194.2020.1856835
[26] Malani D, Murumägi A, Yadav B, et al. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML[J]. Leukemia, 2017, 31(5): 1187-1195. doi: 10.1038/leu.2016.314
[27] Cerrano M, Chevret S, Raffoux E, et al. Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis[J]. Ann Hematol, 2023, 102(4): 761-768. doi: 10.1007/s00277-023-05119-3
[28] Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical Practice-Evidence-Based approach from the writing committee of the american society for apheresis: the eighth special issue[J]. J Clin Apher, 2019, 34(3): 171-354. doi: 10.1002/jca.21705
[29] Lee H, Han JH, Kim JK, et al. Effectiveness of leukapheresis on early survival in acute myeloid leukemia: An observational propensity score matching cohort study[J]. J Clin Apher, 2023, 38(6): 727-737. doi: 10.1002/jca.22090
[30] Zhang D, Zhu Y, Jin Y, et al. Leukapheresis and Hyperleukocytosis, Past and Future[J]. Int J Gen Med, 2021, 14: 3457-3467. doi: 10.2147/IJGM.S321787
[31] Stahl M, Shallis RM, Wei W, et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia(AML)on short-and long-term clinical outcomes: a large, retrospective, multicenter, international study[J]. Leukemia, 2020, 34(12): 3149-3160. doi: 10.1038/s41375-020-0783-3
[32] Schmidt F, Erlacher M, Niemeyer C, et al. Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML[J]. Front Pediatr, 2022, 10: 1046586. doi: 10.3389/fped.2022.1046586
[33] Libourel EJ, Klerk CPW, van Norden Y, et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia[J]. Blood, 2016, 128(14): 1854-1861. doi: 10.1182/blood-2016-02-701094
-
计量
- 文章访问数: 265
- PDF下载数: 25
- 施引文献: 0
下载: